Bartter syndrome type 4a is an autosomal recessive inherited renal tubulopathy characterized by renal salt wasting, hypokalemic metabolic alkalosis, and congenital or early-onset sensorineural deafness. It is caused by pathogenic variants in the BSND gene, which encodes barttin, a subunit necessary for the function of the ClC-Ka and ClC-Kb chloride channels in the kidney and inner ear.
Bartter syndrome type 4A
The BSND gene provides instructions for making barttin, an accessory protein that enables the trafficking, stability, and activity of the ClC-Ka and ClC-Kb chloride channels. These channels are expressed in the thick ascending limb of the loop of Henle, the distal tubule, and structures of the inner ear. In the kidney, they are involved in chloride reabsorption and contribute to the maintenance of sodium, potassium, water, and extracellular volume balance.
When pathogenic variants exist in the BSND gene, barttin is deficient or dysfunctional, and the activity of both chloride channels is altered. This dysfunction leads to salt-losing nephropathy with activation of the renin-angiotensin-aldosterone system, hypokalemia, hypochloremia, and metabolic alkalosis, usually with normal or low blood pressure. In the inner ear, altered ClC-K channels compromise the endochoclear potential necessary for hearing, explaining the characteristic sensorineural deafness. The disorder is inherited in an autosomal recessive manner. Overall, Bartter syndrome is rare, with an estimated incidence close to 1 in 1,000,000 live births; type 4a is one of the less frequent subtypes.
Symptoms
The onset is usually antenatal or neonatal, although the severity can vary depending on the residual protein activity. During pregnancy, polyhydramnios and premature birth due to fetal polyuria may be observed. After birth, patients present with polyuria, polydipsia, dehydration, vomiting or feeding difficulties, failure to thrive, weakness due to hypokalemia, and metabolic alkalosis. Bilateral sensorineural hearing loss, often profound, is a hallmark feature and can be detected on newborn hearing screening. In some patients, nephrocalcinosis or progressive decline in renal function may occur.
Disease management
Management is supportive and aims to maintain hydroelectrolytic balance, promote growth, and prevent renal complications. It requires adequate fluid intake, oral supplements of sodium, chloride, and potassium, and in some cases non-steroidal anti-inflammatory drugs like indomethacin to reduce prostaglandin production and renal salt loss. Potassium-sparing drugs may be used on an individualized basis. Hearing loss is addressed with audiological follow-up, hearing aids, or cochlear implants. Regular nephrological follow-up is necessary with control of electrolytes, growth, renal function, and possible adverse effects of treatment.
Genes analyzed
Bibliography
Shajan AM, Kumar M, Navaneethan P, et al. An Unusual Case of BSND Gene-Related (Type IV) Bartter Syndrome Presenting as Antenatal Bartter Syndrome: A Case Report and Review of Literature. Matern Fetal Med. 2023 Jan 26;5(2):128-130.
Nozu K, Yamamura T, Horinouchi T, et al. Inherited salt-losing tubulopathy: An old condition but a new category of tubulopathy. Pediatr Int. 2020 Apr;62(4):428-437.
Hernández NEG, Pérez LIE, Aguilera D, et al. Clinical Findings and Genetic Analysis of Nine Mexican Families with Bartter Syndrome. Arch Med Res. 2023 Sep;54(6):102859.
